EP0260610A3 - Monoclonal antibodies against human tumour necrotic factor (tnf), and their use - Google Patents

Monoclonal antibodies against human tumour necrotic factor (tnf), and their use Download PDF

Info

Publication number
EP0260610A3
EP0260610A3 EP87113278A EP87113278A EP0260610A3 EP 0260610 A3 EP0260610 A3 EP 0260610A3 EP 87113278 A EP87113278 A EP 87113278A EP 87113278 A EP87113278 A EP 87113278A EP 0260610 A3 EP0260610 A3 EP 0260610A3
Authority
EP
European Patent Office
Prior art keywords
tnf
monoclonal antibodies
antibodies against
against human
human tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87113278A
Other languages
German (de)
Other versions
EP0260610A2 (en
EP0260610B1 (en
Inventor
Achim Dr. Moeller
Franz Dr. Emling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to AT87113278T priority Critical patent/ATE93895T1/en
Publication of EP0260610A2 publication Critical patent/EP0260610A2/en
Publication of EP0260610A3 publication Critical patent/EP0260610A3/en
Priority to MX9203511A priority patent/MX9203511A/en
Application granted granted Critical
Publication of EP0260610B1 publication Critical patent/EP0260610B1/en
Priority to LV960296A priority patent/LV5784B4/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP87113278A 1986-09-13 1987-09-11 Monoclonal antibodies against human tumour necrotic factor (tnf), and their use Expired - Lifetime EP0260610B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT87113278T ATE93895T1 (en) 1986-09-13 1987-09-11 MONOCLONAL ANTIBODIES ANTI-HUMAN TUMONIC CROSS FACTOR (TNF) AND THEIR USE.
MX9203511A MX9203511A (en) 1986-09-13 1992-06-26 MONOKIONALE ANTIKORPER GEGEN HUMANEN TUMONEKROSEIATOR (TNF) UND DEREN VERWENDUNG.
LV960296A LV5784B4 (en) 1986-09-13 1996-07-22 Human growth necrosis factor monoclonal antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863631229 DE3631229A1 (en) 1986-09-13 1986-09-13 MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
DE3631229 1986-09-13

Publications (3)

Publication Number Publication Date
EP0260610A2 EP0260610A2 (en) 1988-03-23
EP0260610A3 true EP0260610A3 (en) 1989-01-11
EP0260610B1 EP0260610B1 (en) 1993-09-01

Family

ID=6309540

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87113278A Expired - Lifetime EP0260610B1 (en) 1986-09-13 1987-09-11 Monoclonal antibodies against human tumour necrotic factor (tnf), and their use

Country Status (11)

Country Link
US (1) US5231024A (en)
EP (1) EP0260610B1 (en)
JP (2) JP2837160B2 (en)
BG (1) BG62229B2 (en)
BR (1) BR1100843A (en)
CA (1) CA1337717C (en)
DE (2) DE3631229A1 (en)
DK (1) DK473887A (en)
ES (1) ES2058083T3 (en)
FI (1) FI91421C (en)
ZA (1) ZA876807B (en)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US5700466A (en) * 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
GB2233559B (en) * 1988-03-11 1992-03-04 Celltech Ltd Antibodies for use in antilymphocyte antibody therapy
DE3823804A1 (en) * 1988-07-14 1990-01-18 Basf Ag NEUTRALIZATION OF THE TOXIC PROPERTIES OF TNF- (ALPHA) IN VITRO AND VIVO BY MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM
WO1990000902A1 (en) * 1988-07-18 1990-02-08 Chiron Corporation Monoclonal antibodies reactive with cachectin
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
DE10399036I1 (en) * 1989-08-07 2004-04-01 Peptide Technology Ltd Binding ligand for tumor necrosis factor.
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
JPH05501351A (en) * 1989-08-16 1993-03-18 カイロン　コーポレイション Cleavage site blocking antibodies against prohormone proteins and uses thereof
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE07012625T1 (en) * 1991-03-18 2010-01-21 New York University Monoclonal and chimeric antibodies to human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2121907T3 (en) * 1992-08-28 1998-12-16 Bayer Ag USE OF ANTI-TNF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF BACTERIAL MENINGITIS.
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
DE4409513C1 (en) * 1994-02-07 1995-10-19 Knoll Ag Use of anti-TNF antibodies as a medicine for the treatment of diseases with an increased interleukin-6 serum level
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU221984B1 (en) 1996-02-09 2003-03-28 Basf Ag Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
ATE488250T1 (en) * 1999-03-02 2010-12-15 Centocor Inc ANTIBODIES AGAINST TNF ALPHA FOR THE THERAPY OF STEROID-RESISTANT ASTHMA
TR200102688T2 (en) * 1999-03-18 2002-01-21 Celgene Corporation Substituted 1-oxo and 1,3-dioxoisoindolins and their use in pharmaceutical compositions for reducing inflammatory cytokine levels.
JP2003511355A (en) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト Endothelin signaling pathway inhibitors and αvβ3 receptor antagonists for combination therapy
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20020168360A1 (en) * 2001-03-02 2002-11-14 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
DK1944322T3 (en) * 2002-07-19 2015-06-22 Abbvie Biotechnology Ltd Treatment of TNFalfa-related diseases
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4754219B2 (en) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド Antibodies directed against tumor necrosis factor and their use
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
KR20110094361A (en) 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
EP2286804A1 (en) 2003-05-13 2011-02-23 DePuy Spine, Inc. A method of treating degenerative disc disease
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
UA89481C2 (en) 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
EP1750754A4 (en) * 2004-03-31 2010-09-22 Centocor Ortho Biotech Inc Human glp-1 mimetibodies, compositions, methods and uses
TW201705980A (en) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
PA8672101A1 (en) 2005-04-29 2006-12-07 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
JP5757495B2 (en) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド Use of TNF inhibitors for the treatment of erosive polyarthritis
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
WO2007015128A1 (en) * 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US9017662B2 (en) 2005-08-30 2015-04-28 Actogenix N.V. Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
BRPI0618085A2 (en) 2005-11-01 2011-08-16 Abbott Biotech Ltd Processes and kits for diagnosis of ankylosing spondylitis using biomarkers
HUE049832T2 (en) 2005-12-29 2020-10-28 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, method and uses
CA2647029A1 (en) 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2708242A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN107158376A (en) * 2006-05-22 2017-09-15 埃克斯生物科技公司 Use the anti-Alpha antibodies treating cancers of IL 1
EP2043711A4 (en) 2006-06-30 2017-08-30 AbbVie Biotechnology Ltd Automatic injection device
EP2851064A3 (en) 2006-07-11 2015-08-05 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
JP2010500360A (en) 2006-08-10 2010-01-07 アルボア コーポレーション Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors
EP2089428B1 (en) 2006-10-27 2013-11-20 AbbVie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
MX2009010361A (en) 2007-03-29 2009-10-16 Abbott Lab Crystalline anti-human il-12 antibodies.
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
CN101980722A (en) * 2007-08-08 2011-02-23 雅培制药有限公司 Compositions and methods for crystallizing antibodies
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
WO2009083246A1 (en) * 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
EP3085773B1 (en) * 2008-05-30 2020-03-18 XBiotech, Inc Uses of il-1 alpha antibodies
US8242074B2 (en) * 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
JP5933975B2 (en) 2008-11-12 2016-06-15 メディミューン，エルエルシー Antibody preparation
BRPI1012162A2 (en) 2009-04-29 2016-01-12 Abbott Biotech Ltd automatic injection device
AU2010315547C1 (en) 2009-10-26 2015-06-04 Société des Produits Nestlé S.A. Assays for the detection of anti-TNF drugs and autoantibodies
BR112012014710A2 (en) 2009-12-15 2017-07-25 Abbott Biotech Ltd optimized ignition button for automatic injection device
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
CN102946904A (en) 2010-06-18 2013-02-27 埃克斯生物科技公司 Arthritis treatment
DK2608808T3 (en) 2010-08-23 2017-04-24 Xbiotech Inc TREATMENT OF NEOPLASTIC DISEASES
KR101934247B1 (en) 2010-10-18 2019-01-02 네스텍 소시에테아노님 Methods for determining anti-drug antibody isotypes
AR084210A1 (en) * 2010-12-08 2013-05-02 Abbott Lab PROTEINS OF UNION TO TNF-a
PE20141436A1 (en) 2011-01-24 2014-11-15 Abbvie Biotechnology Ltd AUTOMATIC INJECTION DEVICES WITH OVERMOLDED GRIPPING SURFACES
SG10201600575WA (en) 2011-01-24 2016-02-26 Abbvie Biotechnology Ltd Removal of needle shields from syringes and automatic injection devices
CN103502815B (en) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 Detect the determination method for the autoantibody of anti-TNF alpha medicine
US8658171B2 (en) 2011-02-28 2014-02-25 Livzon Mabpharm Inc. Humanized anti-TNFα antibodies
CN102675460B (en) 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 The humanized antibody of Tumor necrosis factorα
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
PT2750709T (en) 2011-09-23 2018-11-22 Xbiotech Inc Cachexia treatment
CA2853357A1 (en) * 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
AR088514A1 (en) * 2011-10-24 2014-06-18 Abbvie Inc BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014151901A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
SG11201504260UA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
DK2970980T3 (en) 2013-03-15 2018-10-22 Janssen Biotech Inc METHODS FOR MANAGING C-TERMINAL LYSIN, GALACTOSE AND SIALINIC ACID CONTENTS IN RECOMBINANT PROTEINS
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3145951A1 (en) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Methods of purifying antibodies
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
WO2016088104A2 (en) 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
MX2019008989A (en) 2017-01-30 2019-10-09 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis.
CN110418652A (en) 2017-02-07 2019-11-05 詹森生物科技公司 For treating the anti-TNF antibodies, composition and method of activity ankylosing spondylitis
JP7145162B2 (en) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド Treatment of hidradenitis suppurativa
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EA202192038A1 (en) 2019-01-23 2021-10-05 Янссен Байотек, Инк. ANTIBODY COMPOSITIONS TO TNF FOR USE IN METHODS FOR TREATMENT OF PSORIATIC ARTHRITIS
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
EA202192508A1 (en) 2019-03-14 2022-03-29 Янссен Байотек, Инк. METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220029593A (en) 2019-06-03 2022-03-08 얀센 바이오테크 인코포레이티드 Anti-TNF antibody compositions, and methods for the treatment of psoriatic arthritis
JP2022535534A (en) 2019-06-03 2022-08-09 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF Antibodies, Compositions and Methods for Treating Active Ankylosing Spondylitis
JP2022540764A (en) 2019-06-25 2022-09-20 プロサイセデクス インコーポレイティド Detection of anti-TNFα biologics and anti-drug antibodies
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN117440967A (en) 2020-12-09 2024-01-23 怡诺安有限公司 anti-OX 40L antibodies, anti-OX 40L/anti-TNFa bispecific antibodies and uses thereof
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218868A2 (en) * 1985-08-29 1987-04-22 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780914B2 (en) * 1984-04-02 1995-08-30 旭化成工業株式会社 Antibodies to human tumor necrosis factor
JPS60209528A (en) * 1984-04-03 1985-10-22 Asahi Chem Ind Co Ltd Purification of human tumor necrosis factor
JPS6163698A (en) * 1984-09-05 1986-04-01 Asahi Chem Ind Co Ltd Monoclonal antibody against physiologically active substance and method for purifying physiologically active substance using same
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218868A2 (en) * 1985-08-29 1987-04-22 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Band 104, Nr. 11, 17. März 1986, Seite 534, Zusammenfassung Nr. 86989e, Columbus, Ohio, US; & JP-A-60 208 924 (ASAHI CHEMICAL INDUSTRY CO., LTD) 21-10-1985 *
CHEMICAL ABSTRACTS, Band 104, Nr. 9, 3. März 1986, Seite 562, Zusammenfassung Nr. 67346b, Columbus, Ohio, US; & JP-A-60 209 528 (ASAHI CHEMICAL INDUSTRY CO., LTD) 22-10-1985 *
CHEMICAL ABSTRACTS, Band 105, Nr. 23, 8. Dezember 1986, Seite 451, Zusammenfassung Nr. 207220d, Columbus, Ohio, US; H. HAYASHI et al.: "An enzyme-linked immunosorbent assay for recombinant human tumor necrosis factor using monoclonal antibody", & RECENT ADV. CHEMOTHER. PROC. INT. CONGR. CHEMOTHER. 14TH 1985, ANTICANCER SECT. 2, 820-1 *
CHEMICAL ABSTRACTS, Band 105, Nr. 25, 22. Dezember 1986, Seite 612, Zusammenfassung Nr. 224436w, Columbus, Ohio, US; & JP-A-61 63 698 (ASAHI CHEMICAL INDUSTRY CO., LTD) 01-04-1986 *
CHEMICAL ABSTRACTS, Band 105, Nr. 5, 4. August 1986, Seite 579, Zusammenfassung Nr. 40912s, Columbus, Ohio, US; C.M. LIANG et al.: "Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin", & BIOCHEM. BIOPHYS. RES. COMMUN. 1986, 137(2), 847-54 *

Also Published As

Publication number Publication date
EP0260610A2 (en) 1988-03-23
DE3787241D1 (en) 1993-10-07
ZA876807B (en) 1989-05-30
JP2758394B2 (en) 1998-05-28
FI91421B (en) 1994-03-15
DK473887A (en) 1988-03-11
EP0260610B1 (en) 1993-09-01
ES2058083T3 (en) 1994-11-01
FI873948A0 (en) 1987-09-11
BG62229B2 (en) 1999-05-31
DK473887D0 (en) 1987-09-11
US5231024A (en) 1993-07-27
JPS63157977A (en) 1988-06-30
BR1100843A (en) 2000-04-18
CA1337717C (en) 1995-12-12
FI873948A (en) 1988-03-14
JP2837160B2 (en) 1998-12-14
JPH09294584A (en) 1997-11-18
FI91421C (en) 1994-06-27
DE3631229A1 (en) 1988-03-24

Similar Documents

Publication Publication Date Title
EP0260610A3 (en) Monoclonal antibodies against human tumour necrotic factor (tnf), and their use
IL78444A (en) Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0161941A3 (en) Monoclonal antibody useful in the diagnosis of human stomach or breast cancer
EP0314231A3 (en) Multileaf collimator and related apparatus
IL94872A0 (en) Antibodies reactive with human carcinomas
JPS6460373A (en) Human cells and trioner, antibody and trasformer derived from said cells
AU6785987A (en) Selecting and testing antibodies for cancer therapy
IL88145A0 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
ZA852438B (en) Antibodies,manufacture and use
AU4688785A (en) Monoclonal antibodies to glycoconjugates and use in cancer detection and treatment
EP0240344A3 (en) Monoclonal antibodies and their use
GR3017339T3 (en) C20 Through C26 amino steroids.
HK21795A (en) Cross-protective human monoclonal antibody compositions
DE3476761D1 (en) Unsaturated polyamidemacromeres, their preparation and their use
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
IL85955A0 (en) Human tumor-associated antigen
AU4705185A (en) Medical device, its preparation and use
EP0131627A4 (en) Specific cea-family antigens, antibodies specific thereto and their methods of use.
EP0284613A4 (en) Ultrasound therapy device.
EP0285511A3 (en) Monoclonal antibodies and their uses
DE3279834D1 (en) 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
EP0203967A4 (en) Onco-fetal specific monoclonal antibodies, methods of preparation and use.
IL83342A0 (en) Monoclonal antibodies,their preparation and their use
EP0259807A3 (en) Complement-dependent cytolytic anti-trichomonas vaginalis monoclonal antibody and use thereof in therapy and in diagnosis
PT81454B (en) Monoclonal antibodies specific for human squamous lung carcinoma cells their preparation and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19890103

17Q First examination report despatched

Effective date: 19911028

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 93895

Country of ref document: AT

Date of ref document: 19930915

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3787241

Country of ref document: DE

Date of ref document: 19931007

ITF It: translation for a ep patent filed

Owner name: ING. C. GREGORJ S.P.A.

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19930927

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2058083

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 87113278.3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040809

Year of fee payment: 18

Ref country code: AT

Payment date: 20040809

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040812

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040902

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20040903

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20040914

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20040920

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20040928

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20040930

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050911

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050911

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050912

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060401

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060401

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20060401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20050912

BERE Be: lapsed

Owner name: *BASF A.G.

Effective date: 20050930